Werewolf Therapeutics (HOWL)
Werewolf Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, financials, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
2.4M
Short interest
settlement 2026-10-15
5.1
Days to cover
+1.4 days vs prior
41.5%
Short share of volume
2026-11-03
64,216
Fails to deliver
settlement 2026-10-13
Fri 26 Mar
Next earnings
estimated date
$0
Insider flow, 90 days
0 buys, 0 sells
As of 2026-11-03.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in HOWL is 2,356,300 shares, up 650,344 shares over the last month. Over the last 48 readings it ranged from 667,626 shares (15 May 2026) to 2,511,400 shares (30 September 2026). The latest reading sits at the top of that range. At the reported average volume of 462K shares a day that is 5.1 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/howl" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 2,356,300 | -6.2% | 462,233 | 5.10 |
| 2026-09-30 | 2,511,400 | +47.2% | 679,291 | 3.70 |
| 2026-09-15 | 1,705,956 | +2.3% | 897,287 | 1.90 |
| 2026-08-31 | 1,668,357 | +56.3% | 35,561,049 | 1.00 |
| 2026-08-14 | 1,067,589 | -2.9% | 288,605 | 3.70 |
| 2026-07-31 | 1,099,472 | +17.7% | 844,069 | 1.30 |
| 2026-07-15 | 934,340 | +10.3% | 910,820 | 1.03 |
| 2026-06-30 | 847,096 | -12.2% | 1,096,512 | 1.00 |
| 2026-06-15 | 964,624 | +1.6% | 495,747 | 1.95 |
| 2026-05-29 | 949,598 | +42.2% | 609,217 | 1.56 |
| 2026-05-15 | 667,626 | -8.2% | 678,465 | 1.00 |
| 2026-04-30 | 726,859 | -7.7% | 306,087 | 2.37 |
| 2026-04-15 | 787,448 | -43.1% | 370,648 | 2.12 |
| 2026-03-31 | 1,383,049 | -1.4% | 271,024 | 5.10 |
| 2026-03-13 | 1,402,079 | -32.3% | 497,946 | 2.82 |
| 2026-02-27 | 2,069,809 | +1.0% | 412,094 | 5.02 |
| 2026-02-13 | 2,050,094 | -15.3% | 329,823 | 6.22 |
| 2026-01-30 | 2,419,408 | +5.8% | 522,565 | 4.63 |
| 2026-01-15 | 2,286,905 | +7.9% | 486,805 | 4.70 |
| 2025-12-31 | 2,118,631 | +45.1% | 1,301,783 | 1.63 |
| 2025-12-15 | 1,459,615 | +42.4% | 476,178 | 3.07 |
| 2025-11-28 | 1,025,313 | +32.5% | 475,809 | 2.15 |
| 2025-11-14 | 774,065 | -14.3% | 689,093 | 1.12 |
| 2025-10-31 | 902,853 | +9.6% | 767,632 | 1.18 |
| 2025-10-15 | 824,144 | -3.7% | 1,722,519 | 1.00 |
| 2025-09-30 | 855,811 | +4.0% | 1,359,548 | 1.00 |
| 2025-09-15 | 822,835 | -3.0% | 175,317 | 4.69 |
| 2025-08-29 | 848,163 | -13.6% | 119,967 | 7.07 |
| 2025-08-15 | 982,023 | +19.7% | 144,872 | 6.78 |
| 2025-07-31 | 820,473 | -21.1% | 311,770 | 2.63 |
| 2025-07-15 | 1,040,128 | -21.4% | 382,843 | 2.72 |
| 2025-06-30 | 1,324,074 | -27.9% | 717,052 | 1.85 |
| 2025-06-13 | 1,835,810 | -11.5% | 583,844 | 3.14 |
| 2025-05-30 | 2,073,640 | -6.8% | 832,325 | 2.49 |
| 2025-05-15 | 2,223,949 | +3.5% | 429,265 | 5.18 |
| 2025-04-30 | 2,148,589 | -4.9% | 204,923 | 10.48 |
| 2025-04-15 | 2,260,236 | +15.4% | 298,622 | 7.57 |
| 2025-03-31 | 1,958,872 | -2.3% | 248,529 | 7.88 |
| 2025-03-14 | 2,004,964 | +1.9% | 228,834 | 8.76 |
| 2025-02-28 | 1,967,930 | +5.5% | 270,915 | 7.26 |
| 2025-02-14 | 1,865,039 | +4.0% | 294,666 | 6.33 |
| 2025-01-31 | 1,793,869 | -3.4% | 223,104 | 8.04 |
| 2025-01-15 | 1,856,590 | +7.9% | 339,821 | 5.46 |
| 2024-12-31 | 1,720,256 | +12.9% | 341,302 | 5.04 |
| 2024-12-13 | 1,523,782 | +23.4% | 374,974 | 4.06 |
| 2024-11-29 | 1,234,994 | -5.9% | 489,007 | 2.53 |
| 2024-11-15 | 1,312,267 | +6.9% | 652,003 | 2.01 |
| 2024-10-31 | 1,227,736 | +58.2% | 2,345,342 | 1.00 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 3 November 2026, the short share of HOWL volume is 41.5%, down 16.9 points over the last five sessions. Over the last 30 readings it ranged from 8.5% (2 October 2026) to 79.5% (20 October 2026). The latest reading is in line with the 30-session average of 42.1%, on 120K shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-03 | 50K | 120K | 41.5% | 0 |
| 2026-11-02 | 50K | 119K | 42.2% | 2,023 |
| 2026-10-30 | 101K | 206K | 48.9% | 1,529 |
| 2026-10-29 | 57K | 172K | 33.2% | 0 |
| 2026-10-28 | 53K | 182K | 29.1% | 0 |
| 2026-10-27 | 90K | 155K | 58.4% | 0 |
| 2026-10-26 | 41K | 118K | 35.0% | 0 |
| 2026-10-23 | 60K | 134K | 44.9% | 0 |
| 2026-10-22 | 46K | 86K | 53.0% | 0 |
| 2026-10-21 | 59K | 111K | 52.9% | 0 |
| 2026-10-20 | 247K | 310K | 79.5% | 3,907 |
| 2026-10-19 | 103K | 195K | 53.0% | 0 |
| 2026-10-16 | 106K | 156K | 67.5% | 0 |
| 2026-10-15 | 131K | 241K | 54.2% | 0 |
| 2026-10-14 | 180K | 340K | 52.9% | 0 |
| 2026-10-13 | 129K | 171K | 75.8% | 0 |
| 2026-10-12 | 351K | 551K | 63.7% | 0 |
| 2026-10-09 | 99K | 356K | 27.7% | 0 |
| 2026-10-08 | 58K | 135K | 43.2% | 0 |
| 2026-10-07 | 33K | 155K | 21.1% | 3,200 |
| 2026-10-06 | 48K | 142K | 33.9% | 0 |
| 2026-10-05 | 37K | 84K | 44.1% | 0 |
| 2026-10-02 | 19K | 220K | 8.5% | 0 |
| 2026-10-01 | 45K | 141K | 32.3% | 0 |
| 2026-09-30 | 73K | 307K | 23.9% | 0 |
| 2026-09-29 | 228K | 473K | 48.2% | 0 |
| 2026-09-28 | 40K | 235K | 17.2% | 0 |
| 2026-09-25 | 95K | 204K | 46.5% | 3,000 |
| 2026-09-24 | 26K | 144K | 17.8% | 11,700 |
| 2026-09-23 | 21K | 165K | 12.5% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 13 October 2026, the fails-to-deliver balance in HOWL is 64,216 shares, up 49,688 shares over the last settlement date. Over the last 30 readings it ranged from 1 share (6 October 2026) to 380,485 shares (22 June 2026).
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-13 | 64,216 | $0.98 | $63K |
| 2026-10-09 | 14,528 | $0.91 | $13K |
| 2026-10-08 | 9,617 | $0.92 | $9K |
| 2026-10-06 | 1 | $0.93 | $1 |
| 2026-09-30 | 3,620 | $0.91 | $3K |
| 2026-09-25 | 8,360 | $0.98 | $8K |
| 2026-09-14 | 39 | $0.98 | $38 |
| 2026-09-08 | 18,443 | $0.97 | $18K |
| 2026-09-04 | 43,713 | $0.94 | $41K |
| 2026-08-31 | 4,677 | $0.94 | $4K |
| 2026-08-27 | 27,206 | $0.99 | $27K |
| 2026-08-26 | 129,252 | $0.89 | $115K |
| 2026-08-25 | 140,181 | $0.88 | $123K |
| 2026-08-24 | 35,519 | $0.87 | $31K |
| 2026-08-21 | 247,741 | $0.43 | $107K |
| 2026-08-12 | 112 | $0.38 | $43 |
| 2026-08-11 | 306 | $0.38 | $116 |
| 2026-08-03 | 63 | $0.35 | $22 |
| 2026-07-29 | 3,498 | $0.45 | $2K |
| 2026-07-27 | 49,823 | $0.43 | $21K |
| 2026-07-23 | 3,108 | $0.37 | $1K |
| 2026-07-21 | 17,436 | $0.37 | $6K |
| 2026-07-07 | 94 | $0.32 | $30 |
| 2026-07-01 | 168,564 | $0.36 | $61K |
| 2026-06-30 | 26,535 | $0.31 | $8K |
| 2026-06-26 | 930 | $0.33 | $307 |
| 2026-06-25 | 258,032 | $0.37 | $95K |
| 2026-06-22 | 380,485 | $0.35 | $133K |
| 2026-06-18 | 100,013 | $0.34 | $34K |
| 2026-06-16 | 73,860 | $0.39 | $29K |
Insider trades
SEC Form 4, newest first. JSONNo open-market insider trades were reported for HOWL in the last 90 days. The most recent filings are listed below. Latest filing: EVNIN LUKE (Director) on 2026-07-07.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-07-07 | EVNIN LUKE | Director | Sell | 107K | $0.31 | $33K | 0 |
| 2026-07-06 | EVNIN LUKE | Director | Sell | 36K | $0.32 | $11K | 107K |
| 2026-06-29 | EVNIN LUKE | Director | Sell | 157K | $0.30 | $47K | 143K |
| 2026-06-17 | RA CAPITAL MANAGEMENT, L.P. | TenPercentOwner | Sell | 28K | $0.35 | $10K | 304K |
| 2026-06-17 | RA CAPITAL MANAGEMENT, L.P. | TenPercentOwner | Sell | 389K | $0.35 | $136K | 4.3M |
| 2026-06-16 | RA CAPITAL MANAGEMENT, L.P. | TenPercentOwner | Sell | 10K | $0.37 | $4K | 331K |
| 2026-06-16 | RA CAPITAL MANAGEMENT, L.P. | TenPercentOwner | Sell | 140K | $0.37 | $52K | 4.7M |
| 2026-06-15 | RA CAPITAL MANAGEMENT, L.P. | TenPercentOwner | Sell | 9K | $0.39 | $3K | 341K |
| 2026-06-15 | RA CAPITAL MANAGEMENT, L.P. | TenPercentOwner | Sell | 120K | $0.39 | $47K | 4.8M |
| 2026-06-12 | RA CAPITAL MANAGEMENT, L.P. | TenPercentOwner | Sell | 11K | $0.40 | $5K | 350K |
| 2026-06-12 | RA CAPITAL MANAGEMENT, L.P. | TenPercentOwner | Sell | 159K | $0.40 | $64K | 4.9M |
| 2026-06-11 | Kolchinsky Peter | TenPercentOwner | Sell | 245K | $0.38 | $93K | 5.1M |
| 2026-06-11 | Kolchinsky Peter | TenPercentOwner | Sell | 17K | $0.38 | $7K | 361K |
| 2026-06-11 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sell | 17K | $0.38 | $7K | 361K |
| 2026-06-11 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sell | 245K | $0.38 | $93K | 5.1M |
| 2026-06-10 | Kolchinsky Peter | TenPercentOwner | Sell | 3K | $0.37 | $1K | 379K |
| 2026-06-10 | Kolchinsky Peter | TenPercentOwner | Sell | 43K | $0.37 | $16K | 5.3M |
| 2026-06-10 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sell | 3K | $0.37 | $1K | 379K |
| 2026-06-10 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sell | 43K | $0.37 | $16K | 5.3M |
| 2026-06-09 | Kolchinsky Peter | TenPercentOwner | Sell | 25K | $0.37 | $9K | 382K |
| 2026-06-09 | Kolchinsky Peter | TenPercentOwner | Sell | 345K | $0.37 | $128K | 5.4M |
| 2026-06-09 | EVNIN LUKE | Director | Sell | 77K | $0.37 | $28K | 300K |
| 2026-06-09 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sell | 25K | $0.37 | $9K | 382K |
| 2026-06-09 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sell | 345K | $0.37 | $128K | 5.4M |
| 2026-06-08 | EVNIN LUKE | Director | Sell | 61K | $0.40 | $24K | 377K |
| 2026-06-05 | EVNIN LUKE | Director | Sell | 25K | $0.40 | $10K | 438K |
| 2026-06-04 | EVNIN LUKE | Director | Sell | 20K | $0.44 | $9K | 463K |
| 2026-06-03 | EVNIN LUKE | Director | Sell | 30K | $0.42 | $12K | 483K |
| 2026-06-02 | EVNIN LUKE | Director | Sell | 30K | $0.45 | $13K | 513K |
| 2026-06-01 | EVNIN LUKE | Director | Sell | 80K | $0.47 | $38K | 542K |
| 2026-05-29 | EVNIN LUKE | Director | Sell | 33K | $0.45 | $15K | 623K |
| 2026-05-28 | EVNIN LUKE | Director | Sell | 28K | $0.46 | $13K | 655K |
| 2026-05-27 | EVNIN LUKE | Director | Sell | 81K | $0.48 | $39K | 683K |
| 2026-05-26 | EVNIN LUKE | Director | Sell | 68K | $0.47 | $32K | 764K |
| 2026-05-22 | EVNIN LUKE | Director | Sell | 87K | $0.45 | $39K | 832K |
| 2026-05-21 | EVNIN LUKE | Director | Sell | 36K | $0.42 | $15K | 919K |
| 2026-05-20 | EVNIN LUKE | Director | Sell | 86K | $0.43 | $37K | 955K |
| 2026-05-19 | EVNIN LUKE | Director | Sell | 63K | $0.45 | $28K | 1.0M |
| 2026-05-18 | EVNIN LUKE | Director | Sell | 22K | $0.50 | $11K | 1.1M |
| 2026-05-13 | EVNIN LUKE | Director | Sell | 45K | $0.54 | $24K | 1.1M |
| 2026-05-12 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sell | 7K | $0.64 | $4K | 406K |
| 2026-05-12 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sell | 94K | $0.64 | $60K | 5.7M |
| 2026-05-12 | EVNIN LUKE | Director | Sell | 68K | $0.64 | $43K | 1.2M |
| 2026-05-11 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sell | 6K | $0.67 | $4K | 413K |
| 2026-05-11 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sell | 82K | $0.67 | $55K | 5.8M |
| 2026-05-11 | EVNIN LUKE | Director | Sell | 34K | $0.67 | $23K | 1.2M |
| 2026-05-08 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sell | 25K | $0.71 | $18K | 419K |
| 2026-05-08 | RA CAPITAL MANAGEMENT, L.P. | 10% owner | Sell | 352K | $0.71 | $250K | 5.9M |
| 2026-05-08 | EVNIN LUKE | Director | Sell | 306K | $0.70 | $214K | 1.3M |
| 2026-05-07 | EVNIN LUKE | Director | Sell | 79K | $0.63 | $50K | 1.6M |
| 2026-05-06 | EVNIN LUKE | Director | Sell | 15K | $0.66 | $10K | 1.7M |
| 2026-05-05 | EVNIN LUKE | Director | Sell | 7K | $0.69 | $5K | 1.7M |
| 2026-05-04 | EVNIN LUKE | Director | Sell | 48K | $0.72 | $35K | 1.7M |
| 2026-05-01 | EVNIN LUKE | Director | Sell | 58K | $0.73 | $43K | 1.7M |
| 2026-04-30 | EVNIN LUKE | Director | Sell | 168K | $0.72 | $121K | 1.8M |
| 2026-04-29 | EVNIN LUKE | Director | Sell | 57K | $0.69 | $39K | 2.0M |
| 2026-04-28 | EVNIN LUKE | Director | Sell | 95K | $0.73 | $70K | 2.0M |
| 2026-04-27 | EVNIN LUKE | Director | Sell | 54K | $0.85 | $46K | 2.1M |
| 2026-01-16 | EVNIN LUKE | Director | Sell | 39K | $0.54 | $21K | 2.2M |
| 2026-01-15 | EVNIN LUKE | Director | Sell | 37K | $0.55 | $21K | 2.2M |
| 2026-01-14 | EVNIN LUKE | Director | Sell | 31K | $0.57 | $17K | 2.2M |
| 2026-01-13 | EVNIN LUKE | Director | Sell | 43K | $0.55 | $24K | 2.3M |
| 2026-01-12 | EVNIN LUKE | Director | Sell | 59K | $0.57 | $34K | 2.3M |
| 2026-01-09 | EVNIN LUKE | Director | Sell | 25K | $0.61 | $15K | 2.4M |
| 2026-01-08 | EVNIN LUKE | Director | Sell | 8K | $0.63 | $5K | 2.4M |
| 2026-01-07 | EVNIN LUKE | Director | Sell | 12K | $0.64 | $8K | 2.4M |
| 2026-01-06 | EVNIN LUKE | Director | Sell | 41K | $0.65 | $26K | 2.4M |
| 2026-01-05 | EVNIN LUKE | Director | Sell | 18K | $0.64 | $12K | 2.5M |
| 2026-01-02 | EVNIN LUKE | Director | Sell | 19K | $0.63 | $12K | 2.5M |
| 2025-12-31 | EVNIN LUKE | Director | Sell | 25K | $0.62 | $15K | 2.5M |
| 2025-12-30 | EVNIN LUKE | Director | Sell | 35K | $0.61 | $21K | 2.5M |
| 2025-12-29 | EVNIN LUKE | Director | Sell | 109K | $0.61 | $66K | 2.6M |
| 2025-12-26 | EVNIN LUKE | Director | Sell | 36K | $0.63 | $22K | 2.7M |
| 2025-12-24 | EVNIN LUKE | Director | Sell | 16K | $0.65 | $11K | 2.7M |
| 2025-12-23 | EVNIN LUKE | Director | Sell | 71K | $0.63 | $45K | 2.7M |
| 2025-12-22 | EVNIN LUKE | Director | Sell | 59K | $0.69 | $41K | 2.8M |
| 2025-12-17 | EVNIN LUKE | Director | Sell | 10K | $1.14 | $11K | 2.8M |
| 2025-12-16 | EVNIN LUKE | Director | Sell | 15K | $1.05 | $15K | 2.9M |
| 2025-12-15 | EVNIN LUKE | Director | Sell | 24K | $1.07 | $25K | 2.9M |
| 2025-12-12 | EVNIN LUKE | Director | Sell | 18K | $1.08 | $19K | 2.9M |
| 2025-12-11 | EVNIN LUKE | Director | Sell | 28K | $1.07 | $30K | 2.9M |
| 2025-12-10 | EVNIN LUKE | Director | Sell | 37K | $1.06 | $39K | 2.9M |
| 2025-12-09 | EVNIN LUKE | Director | Sell | 45K | $1.01 | $45K | 3.0M |
| 2025-12-08 | EVNIN LUKE | Director | Sell | 34K | $0.99 | $34K | 3.0M |
| 2025-12-05 | EVNIN LUKE | Director | Sell | 17K | $0.97 | $16K | 3.1M |
| 2025-12-04 | MPM BioImpact LLC | Other | Sell | 83K | $0.97 | $81K | 4.8M |
| 2025-12-04 | MPM BioVentures 2014 (B), L.P. | Other | Sell | 83K | $0.97 | $81K | 4.8M |
| 2025-12-04 | MPM BioVentures 2014, L.P. | Former 10% Owner | Sell | 83K | $0.97 | $81K | 4.8M |
| 2025-12-04 | GADICKE ANSBERT | Former 10% Owner | Sell | 83K | $0.97 | $81K | 4.8M |
| 2025-12-04 | EVNIN LUKE | Director | Sell | 53K | $0.97 | $52K | 3.1M |
| 2025-12-03 | MPM BioImpact LLC | Other | Sell | 57K | $0.87 | $50K | 4.9M |
| 2025-12-03 | MPM BioVentures 2014 (B), L.P. | Other | Sell | 57K | $0.87 | $50K | 4.9M |
| 2025-12-03 | MPM BioVentures 2014, L.P. | Former 10% Owner | Sell | 57K | $0.87 | $50K | 4.9M |
| 2025-12-03 | GADICKE ANSBERT | Former 10% Owner | Sell | 57K | $0.87 | $50K | 4.9M |
| 2025-12-03 | EVNIN LUKE | Director | Sell | 37K | $0.87 | $32K | 3.1M |
| 2025-12-02 | MPM BioImpact LLC | Other | Sell | 59K | $0.89 | $53K | 4.9M |
| 2025-12-02 | MPM BioVentures 2014 (B), L.P. | Other | Sell | 59K | $0.89 | $53K | 4.9M |
| 2025-12-02 | MPM BioVentures 2014, L.P. | Former 10% Owner | Sell | 59K | $0.89 | $53K | 4.9M |
| 2025-12-02 | GADICKE ANSBERT | Former 10% Owner | Sell | 59K | $0.89 | $53K | 4.9M |
| 2025-12-02 | EVNIN LUKE | Director | Sell | 38K | $0.89 | $34K | 3.2M |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON50 Form 144 notices on file for HOWL worth $2.2M at the prices reported; 0 in the last 90 days worth $0. Latest: UBS Oncology Impact Fund, L.P. filed on 2026-01-06 to sell 164,126 shares ($106K) from 2026-01-06.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-01-06 | UBS Oncology Impact Fund, L.P.Shareholder | 164K | $106K | 0.338% | 2026-01-06 | Merrill Lynch |
| 2026-01-06 | MPM Oncology Innovations Fund, L.P.Shareholder | 44K | $28K | 0.090% | 2026-01-06 | Merrill Lynch |
| 2026-01-06 | MPM BioVentures 2014, L.P.Shareholder | 199K | $128K | 0.409% | 2026-01-06 | Merrill Lynch |
| 2026-01-06 | MPM BioVentures 2014 (B), L.P.Shareholder | 13K | $9K | 0.027% | 2026-01-06 | Merrill Lynch |
| 2026-01-06 | MPM Asset Management Investors BV2014 LLCShareholder | 7K | $4K | 0.014% | 2026-01-06 | Merrill Lynch |
| 2026-01-06 | MPM Asset Management LLCShareholder | 31K | $20K | 0.065% | 2026-01-06 | Merrill Lynch |
| 2025-12-29 | UBS Oncology Impact Fund, L.P.Shareholder | 107K | $70K | 0.221% | 2025-12-29 | Merrill Lynch |
| 2025-12-29 | MPM Oncology Innovations Fund, L.P.Shareholder | 29K | $19K | 0.059% | 2025-12-29 | Merrill Lynch |
| 2025-12-29 | MPM BioVentures 2014, L.P.Shareholder | 130K | $85K | 0.268% | 2025-12-29 | Merrill Lynch |
| 2025-12-29 | MPM BioVentures 2014 (B), L.P.Shareholder | 9K | $6K | 0.018% | 2025-12-29 | Merrill Lynch |
| 2025-12-29 | MPM Asset Management Investors BV2014 LLCShareholder | 4K | $3K | 0.009% | 2025-12-29 | Merrill Lynch |
| 2025-12-29 | MPM Asset Management LLCShareholder | 21K | $13K | 0.042% | 2025-12-29 | Merrill Lynch |
| 2025-12-22 | UBS Oncology Impact Fund, L.P.Shareholder | 107K | $74K | 0.221% | 2025-12-22 | Merrill Lynch |
| 2025-12-22 | MPM Oncology Innovations Fund, L.P.Shareholder | 29K | $20K | 0.059% | 2025-12-22 | Merrill Lynch |
| 2025-12-22 | MPM BioVentures 2014, L.P.Shareholder | 130K | $89K | 0.268% | 2025-12-22 | Merrill Lynch |
| 2025-12-22 | MPM BioVentures 2014 (B), L.P.Shareholder | 9K | $6K | 0.018% | 2025-12-22 | Merrill Lynch |
| 2025-12-22 | MPM Asset Management Investors BV2014 LLCShareholder | 4K | $3K | 0.009% | 2025-12-22 | Merrill Lynch |
| 2025-12-22 | MPM Asset Management LLCShareholder | 21K | $14K | 0.042% | 2025-12-22 | Merrill Lynch |
| 2025-12-10 | UBS Oncology Impact Fund, L.P.Shareholder | 73K | $74K | 0.160% | 2025-12-10 | Merrill Lynch |
| 2025-12-10 | MPM Oncology Innovations Fund, L.P.Shareholder | 20K | $20K | 0.043% | 2025-12-10 | Merrill Lynch |
| 2025-12-10 | MPM BioVentures 2014, L.P.Shareholder | 89K | $90K | 0.194% | 2025-12-10 | Merrill Lynch |
| 2025-12-10 | MPM BioVentures 2014 (B), L.P.Shareholder | 6K | $6K | 0.013% | 2025-12-10 | Merrill Lynch |
| 2025-12-10 | MPM Asset Management Investors BV2014 LLCShareholder | 3K | $3K | 0.007% | 2025-12-10 | Merrill Lynch |
| 2025-12-10 | MPM Asset Management LLCShareholder | 14K | $14K | 0.031% | 2025-12-10 | Merrill Lynch |
| 2025-12-03 | UBS Oncology Impact Fund, L.P.Shareholder | 107K | $92K | 0.235% | 2025-12-03 | Merrill Lynch |
| 2025-12-03 | MPM Oncology Innovations Fund, L.P.Shareholder | 29K | $25K | 0.063% | 2025-12-03 | Merrill Lynch |
| 2025-12-03 | MPM BioVentures 2014, L.P.Shareholder | 130K | $112K | 0.285% | 2025-12-03 | Merrill Lynch |
| 2025-12-03 | MPM BioVentures 2014 (B), L.P.Shareholder | 9K | $7K | 0.019% | 2025-12-03 | Merrill Lynch |
| 2025-12-03 | MPM Asset Management Investors BV2014 LLCShareholder | 4K | $4K | 0.010% | 2025-12-03 | Merrill Lynch |
| 2025-12-03 | MPM Asset Management LLCShareholder | 21K | $18K | 0.045% | 2025-12-03 | Merrill Lynch |
| 2025-11-24 | UBS Oncology Impact Fund, L.P.Shareholder | 107K | $94K | 0.235% | 2025-11-24 | Merrill Lynch |
| 2025-11-24 | MPM Oncology Innovations Fund, L.P.Shareholder | 29K | $25K | 0.063% | 2025-11-24 | Merrill Lynch |
| 2025-11-24 | MPM BioVentures 2014, L.P.Shareholder | 130K | $114K | 0.285% | 2025-11-24 | Merrill Lynch |
| 2025-11-24 | MPM BioVentures 2014 (B), L.P.Shareholder | 9K | $8K | 0.019% | 2025-11-24 | Merrill Lynch |
| 2025-11-24 | MPM Asset Management Investors BV2014 LLCShareholder | 4K | $4K | 0.010% | 2025-11-24 | Merrill Lynch |
| 2025-11-24 | MPM Asset Management LLCShareholder | 21K | $18K | 0.045% | 2025-11-24 | Merrill Lynch |
| 2025-11-17 | UBS Oncology Impact Fund, L.P.Shareholder | 107K | $99K | 0.235% | 2025-11-17 | Merrill Lynch |
| 2025-11-17 | MPM Oncology Innovations Fund, L.P.Shareholder | 29K | $26K | 0.063% | 2025-11-17 | Merrill Lynch |
| 2025-11-17 | MPM BioVentures 2014, L.P.Shareholder | 130K | $119K | 0.285% | 2025-11-17 | Merrill Lynch |
| 2025-11-17 | MPM BioVentures 2014 (B), L.P.Shareholder | 9K | $8K | 0.019% | 2025-11-17 | Merrill Lynch |
| 2025-11-17 | MPM Asset Management Investors BV2014 LLCShareholder | 4K | $4K | 0.010% | 2025-11-17 | Merrill Lynch |
| 2025-11-17 | MPM Asset Management LLCShareholder | 21K | $19K | 0.045% | 2025-11-17 | Merrill Lynch |
| 2025-11-10 | UBS Oncology Impact Fund, L.P.Shareholder | 107K | $124K | 0.235% | 2025-11-10 | Merrill Lynch |
| 2025-11-10 | MPM Oncology Innovations Fund, L.P.Shareholder | 29K | $33K | 0.063% | 2025-11-10 | Merrill Lynch |
| 2025-11-10 | MPM BioVentures 2014, L.P.Shareholder | 130K | $150K | 0.285% | 2025-11-10 | Merrill Lynch |
| 2025-11-10 | MPM BioVentures 2014 (B), L.P.Shareholder | 9K | $10K | 0.019% | 2025-11-10 | Merrill Lynch |
| 2025-11-10 | MPM Asset Management Investors BV2014 LLCShareholder | 4K | $5K | 0.010% | 2025-11-10 | Merrill Lynch |
| 2025-11-10 | MPM Asset Management LLCShareholder | 21K | $24K | 0.045% | 2025-11-10 | Merrill Lynch |
| 2025-11-04 | UBS Oncology Impact Fund, L.P.Shareholder | 107K | $141K | 0.235% | 2025-11-04 | Merrill Lynch |
| 2025-11-04 | MPM Oncology Innovations Fund, L.P.Shareholder | 29K | $38K | 0.063% | 2025-11-04 | Merrill Lynch |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON1 holder reports 5% or more of HOWL in its latest filing, on Schedule 13G (passive). The holder is MOLL PETER at 5.2% of the class (2,537,138 shares), filed 2026-09-21 for an event on 2026-09-18.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-09-21 | 13G | MOLL PETERother entity | 2.5M | 5.2% | 2026-09-18 |
| 2026-07-02 | 13D/Ano. 12 | RA Capital Management, L.P.investment adviser, partnership | 2.0M | 4.1% | 2026-06-30 |
| 2026-07-02 | 13D/Ano. 12 | Rajeev Shahparent holding company, individual | 2.0M | 4.1% | 2026-06-30 |
| 2026-07-02 | 13D/Ano. 12 | Peter Kolchinskyparent holding company, individual | 2.0M | 4.1% | 2026-06-30 |
| 2026-07-02 | 13D/Ano. 12 | RA Capital Healthcare Fund, L.P.partnership | 1.9M | 3.8% | 2026-06-30 |
| 2026-05-12 | 13D/Ano. 7 | ANSBERT GADICKEindividual | 1.8M | 3.8% | 2026-05-08 |
| 2026-05-12 | 13D/Ano. 7 | LUKE EVNINindividual | 1.2M | 2.4% | 2026-05-08 |
| 2026-05-12 | 13D/Ano. 7 | MPM BioVentures 2014 LLCother entity | 872K | 1.8% | 2026-05-08 |
| 2026-05-12 | 13D/Ano. 7 | Todd Foleyindividual | 872K | 1.8% | 2026-05-08 |
| 2026-05-12 | 13D/Ano. 7 | MPM BioVentures 2014 GP LLCother entity | 845K | 1.7% | 2026-05-08 |
| 2026-05-12 | 13D/Ano. 7 | MPM BioVentures 2014, L.P.partnership | 792K | 1.6% | 2026-05-08 |
| 2026-05-12 | 13D/Ano. 7 | MPM BioImpact LLCother entity | 655K | 1.3% | 2026-05-08 |
| 2026-05-12 | 13D/Ano. 7 | Oncology Impact Fund (Cayman) Management L.P.partnership | 655K | 1.3% | 2026-05-08 |
| 2026-05-12 | 13D/Ano. 7 | UBS Oncology Impact Fund L.P.partnership | 655K | 1.3% | 2026-05-08 |
| 2026-05-12 | 13D/Ano. 7 | MPM ONCOLOGY INNOVATIONS FUND LPpartnership | 173K | 0.4% | 2026-05-08 |
| 2026-05-12 | 13D/Ano. 7 | MPM Oncology Innovations Fund GP LLCother entity | 173K | 0.4% | 2026-05-08 |
| 2026-05-12 | 13D/Ano. 7 | MPM ASSET MANAGEMENT LLCother entity | 125K | 0.3% | 2026-05-08 |
| 2026-05-12 | 13D/Ano. 7 | MPM Asset Management Investors BV2014 LLCother entity | 27K | 0.1% | 2026-05-08 |
| 2026-05-12 | 13D/Ano. 7 | MPM BioVentures 2014 (B), L.P.partnership | 53K | 0.1% | 2026-05-08 |
| 2026-02-11 | 13G/Ano. 1 | Longwood Fund III, L.P.partnership | 1.7M | 3.5% | 2025-12-31 |
| 2026-02-11 | 13G/Ano. 1 | Longwood Fund III GP, LLCother entity | 1.7M | 3.5% | 2025-12-31 |
13F holders
Tracked managers holding HOWL at their latest 13F. JSON3 of the 30 tracked managers held HOWL at their latest 13F, $275K in total at quarter-end prices. Renaissance Technologies is the largest at $243K (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 1 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Renaissance Technologies | 2026-06-30 | 675K | $243K | 0.00% | +158K |
| Millennium Management | 2026-06-30 | 62K | $22K | 0.00% | -70K |
| Two Sigma Investments | 2026-06-30 | 27K | $10K | 0.00% | new |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
Financials
SEC XBRL, as filed. JSONIn FY 2025 it generated -$60.3M of operating cash flow.
- Cash
- $22.0M
- Equity
- $16.3M
- Total assets
- $24.2M
- Shares outstanding
- 48,599,066
Quarterly, last 8 quarters
| Quarter | Period end | Revenue | Net income | Margin | Diluted EPS |
|---|---|---|---|---|---|
| Q2 FY 2026 | 2026-06-30 | n/a | $3.7M | n/a | 0.08 |
| Q1 FY 2026 | 2026-03-31 | n/a | -$13.5M | n/a | -0.28 |
| Q4 FY 2025derived | 2025-12-31 | n/a | -$8.4M | n/a | n/a |
| Q3 FY 2025 | 2025-09-30 | n/a | -$16.4M | n/a | -0.36 |
| Q2 FY 2025 | 2025-06-30 | n/a | -$18.0M | n/a | -0.40 |
| Q1 FY 2025 | 2025-03-31 | n/a | -$18.1M | n/a | -0.40 |
| Q4 FY 2024derived | 2024-12-31 | n/a | -$20.4M | n/a | n/a |
| Q3 FY 2024 | 2024-09-30 | n/a | -$16.7M | n/a | -0.38 |
Fiscal years, with buybacks and dividends
| Fiscal year | Ends | Revenue | Net income | Operating cash flow | Capex | Buybacks | Dividends |
|---|---|---|---|---|---|---|---|
| FY 2025 | 2025-12-31 | n/a | -$60.8M | -$60.3M | $0 | n/a | n/a |
| FY 2024 | 2024-12-31 | n/a | -$70.5M | -$56.2M | $254K | n/a | n/a |
| FY 2023 | 2023-12-31 | n/a | -$37.4M | -$32.6M | $769K | n/a | n/a |
| FY 2022 | 2022-12-31 | n/a | -$53.8M | -$40.6M | $3.6M | n/a | n/a |
| FY 2021 | 2021-12-31 | n/a | -$50.0M | -$42.9M | $498K | n/a | n/a |
Quarters are the three-month figures the company reports; a fourth quarter marked derived is the fiscal year less the three reported quarters, since companies report it only inside the 10-K. Fiscal years are the annual figures. Buybacks are the cash the company paid to repurchase its common stock in the year, not the amount authorized. Balance sheet lines are as of 2026-06-30; shares outstanding as of 2026-07-27 from the cover page.
What this page is
Werewolf Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Werewolf Therapeutics (HOWL), SEC CIK 1785530, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-03.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-13.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-01-06.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-09-21.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Financials
- SEC EDGAR 10-K and 10-Q filingsSource: SEC.Weekly; values are as filed in the 10-Q and 10-K. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-07-31.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-07-07.JSON and CSV
- Company record
- EDGAR filing index for CIK 1785530Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
Datasets
Frequently Asked Questions
How much of HOWL is sold short?
2,356,300 shares were held short at the 2026-10-15 settlement, 5.1 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is HOWL's daily short volume?
On 2026-11-03, 49,960 of the 120,408 HOWL shares reported to FINRA were sold short, 41.5% of the day's reported volume. Short volume is a flow for one day, not a position.
Does HOWL have fails to deliver?
The SEC's latest file shows 64,216 HOWL shares failed to deliver at settlement 2026-10-13. Fails are reported per settlement date and published twice a month with a lag.
Are HOWL insiders buying or selling?
No open-market insider trades were reported for HOWL in the last 90 days. The most recent filings are listed below. Latest filing: EVNIN LUKE (Director) on 2026-07-07.
Have HOWL insiders filed to sell?
50 Form 144 notices on file for HOWL worth $2.2M at the prices reported; 0 in the last 90 days worth $0. Latest: UBS Oncology Impact Fund, L.P. filed on 2026-01-06 to sell 164,126 shares ($106K) from 2026-01-06.
Who owns 5% or more of HOWL?
1 holder reports 5% or more of HOWL in its latest filing, on Schedule 13G (passive). The holder is MOLL PETER at 5.2% of the class (2,537,138 shares), filed 2026-09-21 for an event on 2026-09-18.
What did HOWL report last quarter?
In FY 2025 it generated -$60.3M of operating cash flow.
Which tracked 13F managers own HOWL?
3 of the 30 tracked 13F managers held HOWL shares at their latest filing, $275K in all. The largest: Renaissance Technologies (675K shares, $243K), Izzy Englander's Millennium Management (62K shares, $22K), Two Sigma Investments (27K shares, $10K).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.